U.S. Markets open in 3 hrs 39 mins

AbbVie Inc. (ABBV)

NYSE - NYSE Delayed Price. Currency in USD
Add to watchlist
94.68-0.83 (-0.87%)
At close: 4:02PM EDT

AbbVie Inc.

1 North Waukegan Road
North Chicago 60064
United States
847 932 7900
http://www.abbvie.com

Sector(s)Healthcare
IndustryDrug Manufacturers—General
Full Time Employees47,000

Key Executives

NameTitlePayExercisedYear Born
Mr. Richard A. GonzalezChairman & CEO7.11MN/A1954
Dr. Michael E. SeverinoVice Chairman & Pres3.98MN/A1966
Mr. Robert A. MichaelExec. VP & CFO2.76MN/A1970
Ms. Laura J. SchumacherVice Chairman of External Affairs, Chief Legal Officer & Corp. Sec.4.3MN/A1963
Mr. Carlos AlbanVice Chairman & Chief Commercial Officer4.08MN/A1963
Amounts are as of December 31, 2019 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the United States, Japan, Germany, Canada, France, Spain, Italy, the Netherlands, the United Kingdom, Brazil, and internationally. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheumatoid arthritis in adult patients; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), mantle cell lymphoma, waldenström's macroglobulinemia, marginal zone lymphoma, and chronic graft versus host disease; VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; VIEKIRA PAK, an interferon-free therapy to treat adults with genotype 1 chronic hepatitis C virus (HCV); TECHNIVIE to treat adults with genotype 4 HCV infection; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection. It also provides SYNAGIS that protects at-risk infants from severe respiratory disease; KALETRA, a prescription anti-HIV-1 medicine; CREON, a pancreatic enzyme therapy for exocrine pancreatic insufficiency; Synthroid used in the treatment of hypothyroidism; AndroGel for males diagnosed with symptomatic low testosterone; and Lupron, a product for the palliative treatment of advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids. In addition, the company offers ORILISSA, a nonpeptide small molecule gonadotropin-releasing hormone antagonist; Duopa and Duodopa, a levodopa-carbidopa intestinal gel to treat Parkinson's disease; and Sevoflurane, an anesthesia product. It has collaborations with Calico Life Sciences LLC; Alector, Inc.; Janssen Biotech, Inc.; Jacobio Pharmaceuticals; and Genmab A/S. The company was incorporated in 2012 and is based in North Chicago, Illinois.

Corporate Governance

AbbVie Inc.’s ISS Governance QualityScore as of December 8, 2019 is 7. The pillar scores are Audit: 2; Board: 5; Shareholder Rights: 9; Compensation: 3.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.